We are live on ! Find out more
CLDI.WS

Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS

Delisted

CLDI.WS was delisted on the 17th of October, 2024.

Back to rankings

22 hedge funds and large institutions have $5.93M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
22
Holders Change
+22
Holders Change %
–
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
–
Reduced
–
Closed
–
Calls
$4.82M
Puts
–
Net Calls
+$4.82M
Net Calls Change
+$4.82M

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$558K
2
AMH
Apollo Management Holdings
New York
+$558K
3
PAMP
Polar Asset Management Partners
Ontario, Canada
+$419K
4
FC
Finepoint Capital
Massachusetts
+$370K
5
BCM
Beryl Capital Management
California
+$355K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$1.96M +$113K +199,999 New
AMH
2
Apollo Management Holdings
New York
$495K +$558K +989,999 New
WP
3
Woodline Partners
California
$495K +$558K +990,000 New
AA
4
AQR Arbitrage
Connecticut
$490K +$28.2K +49,998 New
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$371K +$419K +742,563 New
FC
6
Finepoint Capital
Massachusetts
$328K +$370K +655,200 New
BCM
7
Beryl Capital Management
California
$315K +$355K +629,999 New
HCM
8
Highbridge Capital Management
New York
$254K – – –
SCM
9
Segantii Capital Management
Hong Kong
$245K +$14.1K +25,000 New
BFM
10
Boothbay Fund Management
New York
$222K +$12.8K +22,626 New
GL
11
Governors Lane
New York
$179K +$197K +350,000 New
Parallax Volatility Advisers
12
Parallax Volatility Advisers
California
$162K +$182K +323,142 New
PC
13
Periscope Capital
Ontario, Canada
$144K +$162K +287,400 New
WAM
14
Wolverine Asset Management
Illinois
$57K +$64.5K +114,367 New
6CM
15
683 Capital Management
New York
$51K +$56.4K +100,000 New
QGA
16
Q Global Advisors
Texas
$50K +$56.4K +100,000 New
SAMU
17
SONA Asset Management (US)
New York
$45K +$51.3K +90,898 New
Walleye Capital
18
Walleye Capital
New York
$16K +$17.8K +31,529 New
CCFM
19
Cohen & Co Financial Management
New York
$13K +$14.1K +25,000 New
AGM
20
Alpine Global Management
New York
$13K +$14.2K +25,200 New
PCM
21
Prelude Capital Management
New York
$11K +$12.8K +22,629 New
Walleye Trading
22
Walleye Trading
New York
$10K +$11.3K +20,052 New
UBS Group
23
UBS Group
Switzerland
$1K +$663 +1,175 New

CLDI.WS Hedge Fund Activity: Q4 2021 in Review

22 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q4 2021, worth a combined $5.93M.

Buyers outnumbered sellers: 22 funds opened new CLDI.WS positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Woodline Partners, opening a new position worth an estimated $558K.

  • 22 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $5.93M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q4 2021.
  • 22 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q4 2021 and 0 closed out, a net change of +22 holders.
  • The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q4 2021 was Woodline Partners, an estimated $558K added.

Based on aggregated 13F filings for Q4 2021.